The clinical trial programme for insulin degludec (IDeg) is the largest reported
|
|
- Vivian Cox
- 6 years ago
- Views:
Transcription
1 supplement to Journal of the association of physicians of india january 2014 VOL Treating to Target in Type 2 Diabetes : The BEGIN Trial Programme Subhash K Wangnoo 1, Subhankar Chowdhury 2, PV Rao 3 Abstract Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. The insulin degludec and insulin degludec/insulin aspart clinical trial programme was truly global, involving 40 different countries and encompassing a multitude of ethnic populations. It is the largest insulin development clinical trial programme on record with more than 11,000 patients included worldwide. It includes two main components: BEGIN (insulin degludec studied across the spectrum of diabetes) and BOOST (insulin degludec in a fixed-dose combination with insulin aspart). In clinical trials (phase 2 and phase 3a), insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of nocturnal hypoglycaemia. In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety. A 200 U/mL formulation of insulin degludec is also available for use in patients who require large volumes of basal insulin. Subcutaneous insulin degludec is generally well tolerated in patients with type 1 or 2 diabetes and represents a useful advance in the treatment of type 1 or 2 diabetes. Introduction The clinical trial programme for insulin degludec (IDeg) is the largest reported insulin development clinical trial programme. It includes two main components: BEGIN [IDeg studied across the spectrum of diabetes] and BOOST [IDeg in a fixeddose combination with insulin aspart (IAsp)]. Details of the BEGIN clinical trial programme are presented in this supplement. The BEGIN clinical trial programme (comprising nine trials) involved subjects from 40 countries, encompassing a multitude of ethnic populations. The use of IDeg in both type 1 and early-to-advanced type 2 diabetes was evaluated. Prior to the Phase 3 clinical programme, the drug was evaluated in the laboratory and in Phase 1 pharmacokinetic/pharmacodynamic and Phase 2 programmes. Extent and Aims of Phase 2/3a Programmes 1 Dept. of Endocrinology, Indraprastha Apollo Hospital, New Delhi; 2 Dept. of Endocrinology, IPGME&R and SSKM Hospital, Kolkata; 3 Dept. of Endocrinology, Nizam s Institute of Medical Sciences, Hyderabad Two global phase 2 studies were conducted to provide proof of concept and to explore the efficacy and safety of IDeg in type 1 and type 2 diabetes. 1,2 The promising results from the phase 2 studies of IDeg laid the foundation for the BEGIN phase 3a study programme, which examined the efficacy and safety of IDeg once daily (OD) in three trials in type 1 diabetes (T1D) and six trials in type 2 diabetes (T2D) (Figure 1). The duration of the BEGIN phase 3a trials for IDeg trials was from 26 to 52 weeks, with four trials having extension arms of 26 to 52 weeks. Comparators were insulin glargine (IGlar) (seven trials), insulin detemir (IDet) (one trial) and sitagliptin (one trial) (Figure 1). IDeg was studied across the spectrum of diabetes, including T1D and both early and advanced T2D. The programme included patients from all over the world (North America, South America, Europe, Africa, Asia and Australia) and encompassed a number of different ethnic populations. The majority of exposed patients had T2D, reflecting the large and growing size of this diabetes population. A broad spectrum of insulin regimens for both T1D and T2D were spanned, including basal bolus therapy, basal plus oral therapy, and basal versus oral therapy, and also investigated
2 22 supplement to Journal of the association of physicians of india january 2014 VOL. 62 Fig. 1: Overview of the trials included under the BEGIN programme 3-12 α-gluc, alpha glucosidase inhibitor; BB, basal bolus; BOT, basal oral therapy; DPP4, dipeptidyl peptidase-4 inhibitor; IAsp, insulin aspart; Met, metformin; OADs, oral anti-diabetic drugs; Pio, pioglitazone; SU, sulphonylurea; T1, type 1 diabetes; T2, type 2 diabetes. List of OADs in each box apply to all arms in each trial. flexible dosing options. The extent and breadth of the BEGIN clinical trial programme provides an excellent overview of the potential of IDeg in the treatment of patients with both T1D and T2D compared with other available insulin treatment regimens Common Principles Applied Across Protocols Conduct of the trials All the trials were done in accordance with the Declaration of Helsinki 13 and Good Clinical Practice Guidelines. 14 Signed informed consent was obtained from each participant. The protocol and the consent form for each trial were reviewed and approved by the local independent ethics committee or institutional review board before trial initiation. Treat-to-target design All of the trials in the phase 3a programme were conducted as treat-to-target studies, in accordance with guidance from regulatory authorities such as the Food and Drug Administration (FDA) in the USA. The FDA requirement states that the Test and comparator groups should be treated to similar goals. Similar degrees of glycaemic control (test non-inferior to reference) should be achieved so that comparisons among groups in frequency and severity of hypoglycaemia will be interpretable in ultimate risk-benefit assessments. 15 Using a treat-to-target design means that betweentreatment comparisons of the frequency and severity of hypoglycaemia can be interpreted without being confounded by different levels of glycaemic control. Trial outcome measures/endpoints 3-12 In all the phase 3a trials, the primary endpoint was the difference between treatment groups in the change in HbA1c from baseline to study end. The difference between groups in change in HbA1c was analysed for non-inferiority or superiority. A noninferiority limit of 0.4%-points was set for the treatment difference in the phase 3a trials. Key secondary endpoints included hypoglycaemia rate, fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) profiles, insulin dose, body weight and adverse events (AEs). Some trials also included patient-reported outcomes such as health-related quality of life (HRQoL), using the validated Short Form 36 Health Survey, version 2. Definitions of hypoglycaemia 3-12 All the phase 2 and 3a trials used a standardised algorithm for reporting confirmed hypoglycaemia. Hypoglycaemia was classified as confirmed if a plasma glucose measurement of < 3.1 mmol/l (56 mg/dl) was obtained, irrespective of any symptoms, or if the hypoglycaemia was severe (i.e. assistance from another person was required). Nocturnal hypoglycaemic episodes were defined as those with time of onset between 00h01 and 05h59 inclusively. Insulin dosing Trials in T1D 3-5 If patients had previously used a basal insulin OD, the same number of units OD were prescribed. If prior basal therapy was twice daily, the total basal dose was calculated and administered OD. For IDeg, this involved a 1:1 transfer to the full calculated dose (although dose reductions could be considered at the investigator s discretion), while the IGlar dose was reduced by 20 30%, according to the approved labelling. Trials in T2D 6-12 Insulin-naïve patients and patients who had not previously used basal insulin were given a starting dose of 10 U of IDeg or IGlar. For patients already using a basal insulin OD, the same number of units OD was prescribed. If the prior basal insulin was taken more than OD, total daily basal dose was calculated. If the subject was randomised to IGlar, it was recommended to reduce the administered dose by 20 30%, according to the approved labelling. For subjects randomised to IDeg, a dose reduction was to be considered, according to the investigator s discretion. Titration of basal and bolus insulin 1-12 In the phase 2 studies of IDeg, the titration target was an FPG value of 4 6 mmol/l ( mg/ dl). FPG at the end of these trials did not indicate normoglycaemia, and hypoglycaemia rates were not increased compared with previous treat-to-target
3 supplement to Journal of the association of physicians of india january 2014 VOL studies; therefore, a more ambitious target of mmol/l (70 89 mg/dl) was set for phase 3a. It was considered that, because of the ultra-long duration of action and flat profile of IDeg, it should be possible to administer it at any time of the day. Various administration schedules were used for IDeg OD in the phase 3a programme: morning, evening, mealtime, and at any time during the day. Some studies used a forced flexible regimen, in which IDeg was injected at alternating intervals of 8 hours and 40 hours, or Free-Flex regimens, in which patients were free to choose the time of administration, as long as the interval between injections was 8 40 hours. In all the trials that used IGlar, it was administered at the same time every day, according to its approved product label. Physicians and patients were free to choose the optimal administration time for IGlar for each individual. Pre-specified titration algorithms were used for basal and bolus insulin. Physicians increased or reduced doses, or left it unchanged, according to measured blood glucose values and other relevant information (e.g. hypoglycaemic episodes, known lifestyle changes). In most of the trials, the basal insulin dose was titrated once weekly based on the mean pre-breakfast plasma glucose from the preceding 3 days. For the majority of trials that included bolus insulin supplementation, bolus doses were adjusted based on the mean pre-prandial plasma glucose level measured prior to the next meal or before bedtime. Basal insulin was titrated before bolus insulin doses were adjusted. Inclusion and exclusion criteria 3-12 Inclusion criteria were set to ensure that a representative population was included, and to include only patients with T1D/T2D (as relevant). Exclusion criteria aimed to exclude patients with conditions or using other treatments that could confound the results, or whose safety could be compromised by participating in the trial due to existing co-morbidities, or who were unlikely to be able to follow the injection regimen adequately. Key inclusion criteria for the phase 3a trials: Adults aged >18 years. The trials in T1D required patients to have been diagnosed with it for at least 1 year, and to have been using basal-bolus therapy for at least 1 year before screening. The trials in T2D required patients to have been diagnosed with it for at least 6 months. The trials in T2D included insulin-naïve or insulin-experienced users. For each trial, criteria were set to specify which medications patients had been using, and the duration of previous use. HbA1c < 10% in T1D and in the range of % in T2D. The upper limit was imposed to ensure that patients could control their disease to a certain extent. For T2D, it was considered that patients with HbA1c < 7.0% were already achieving good glycaemic control. BMI < 35 (T1D) or 40 kg/m 2 (T2D). An upper limit of BMI was imposed to exclude individuals with severe insulin resistance. Phase 2 Trials Efficacy and Safety There were 2 phase trials conducted one in T1D and T2D each. Both were clinical exploratory, proofof-concept, 16-week, randomised, controlled, openlabel, three-arm, parallel-group treat-to-target study comparing two formulations of IDeg to IGlar. IDeg Group A was of the same molar concentration as IGlar (600 μmol/l, 1 unit = 6 nmol); IDeg Group B was a higher strength formulation (900 μmol/l; 1 unit = 9 nmol). 1,2 The higher strength formulation was tested for its efficacy and safety and to assess whether any extra benefit can be obtained from it. Type 1 Diabetes 1 There was one phase 2 trial conducted in T1D, using IDeg in a basal-bolus regimen with IAsp at mealtimes versus IGlar as comparator. It included patients with T1D for > 1 year, previously treated continuously with any insulin regimen. Participants were randomised 1:1:1 into three groups: IDeg Group A, IDeg Group B, or IGlar, all given in the evening. IAsp was administered at mealtimes. At 16 weeks, mean A1C was comparable for IDeg (A) (7.8%), IDeg (B) (8.0%), and IGlar (7.6%), as was FPG (8.3, 8.3 and 8.9 mmol/l, respectively). Estimated mean rates of confirmed hypoglycaemia were 28% lower for IDeg (A) and 10% lower for IDeg (B) compared with IGlar; rates of nocturnal hypoglycaemia were 58% lower for IDeg(A) and 29% lower for IDeg(B). At study end, the plasma glucose levels in the nine-point SMPG profiles were reduced in all treatment groups and were similar between groups. Mean total daily insulin dose was similar to baseline (60 units, 49 units and 51 units vs. 60 units, 59 units and 52 units at baseline respectively). The overall rates of adverse events (AEs) for IDeg(A), IDeg(B), and IGlar were 8.7, 6.5, and 9.1 events/patient year. There were no specific patterns or clustering of the AEs; most were mild or moderate in severity and judged to have an unlikely relation to the trial insulin products. No injection-site reactions were reported. Four serious AEs were reported: diabetic ketoacidosis (IGlar), abdominal distension (IDeg(A)), hypoglycaemic unconsciousness (IDeg(A)), and hypoglycaemia (IDeg(B)).
4 24 supplement to Journal of the association of physicians of india january 2014 VOL. 62 At the end of the trial, there were no obvious differences between groups in clinical laboratory tests, ECG, fundoscopy, vital signs, or physical examination. The level of IDeg specific antibodies was close to, or below, the limit of detection at screening and remained at the same level at the end of the treatment period. Type 2 Diabetes 2 There was one phase 2 trial conducted in T2D which included insulin-naïve patients, diagnosed with T2D for > 3 months and with HbA1c % and BMI kg/m 2. Patients were randomised 1:1:1:1 as follows: IDeg (900 μmol/l) three times a week; IDeg Group A; IDeg Group B; IGlar OD. In all the arms, insulin was dosed in combination with metformin. At study end, mean HbA1C levels were much the same across treatment groups, at 7 3%, 7 4%, 7 5%, and 7 2%, respectively. Estimated mean HbA1C treatment differences from IDeg by comparison with IGlar were 0 08% for the three dose per week schedule, 0 17% for group A, and 0 28% for group B. Few participants had hypoglycaemia; however, the proportion of participants who had hypoglycaemia in IDeg group A was lower than was the proportion in the IGlar group and the IDeg three times a week group. The number of adverse events was much the same across groups; most were mild-to-moderate in severity with no apparent treatment specific pattern. Most AEs were mild or moderate in severity, and there was no apparent treatment-specific pattern. Only two serious adverse events were reported: aggravation of a pretrial coronary heart disease in the three times a week IDeg group and worsening of paroxysmal atrial fibrillation in IDeg group B; both events were judged to be unlikely to be related to trial product. AEs judged to have possible or probable relation to insulin were reported for six participants in the IDeg three times a week group (headache, dermatitis, pruritic rash, diarrhoea, stomach discomfort, and peripheral oedema), two participants in IDeg group A (three events; dizziness, dysgeusia, and palpitations), five participants in IDeg group B (headache, increased blood cholesterol, increased weight, pruritus, and muscle spasms), and two participants in the IGlar group (headache and increased blood cholesterol). There were few injection-site reactions. Concentrations of antibodies specific to IDeg and those cross-reacting between IDeg and human insulin were negligible. Based on both these phase two studies, the 900 μmol/l formulation was not developed further, since it showed no added advantage over the conventional formulation. Phase 3a The BEGIN trials There were three phase 3a trials conducted in T1D, using IDeg in a basal-bolus regimen with IAsp at mealtimes versus IGlar as comparator in two, and IDet in one. Both trials versus IGlar had extension periods. BEGIN BB T1 long This was a 52-week, open-label, treat-to-target, non-inferiority trial comparing IDeg with IGlar, which included adults with T1D, who were previously treated with basal-bolus insulin for at least 1 year. Patients were randomly assigned in a 3:1 ratio to IDeg OD or IGlar OD 3. In the 52-week extension period, for the second year, patients maintained their prior randomisation (IDeg:IGlar 3:1). The total duration of the trial was 2 years for patients enrolled in both trial periods. 4 BEGIN flex T1 5 This was a 26-week, open-label, treat-to-target trial comparing a forced-flexible dosing regimen of IDeg ( IDeg Forced-Flex ) with IDeg OD and IGlar OD. It included adults with T1D for 12 months, previously treated with any basal bolus regimen. Subjects were randomised 1:1:1 as follows: IDeg OD administered with the evening meal; IDeg Forced-Flex, where subjects alternated insulin administration timing between morning and evening to create intervals of 8 to 40 hours between insulin doses; and IGlar OD at the same time each day. IAsp was used as prandial insulin in all three treatment groups. The 26-week extension period, investigated the long-term safety and efficacy of IDeg in a free flex regimen ( IDeg Free-Flex ) in combination with meal-time IAsp. For the extension period, patients in the IDeg Free-Flex arm were free to choose the time of administration, provided that the interval between consecutive doses was more than 8 hours and less than 40 hours. The comparator was IGlar OD. The total duration of the trial was 52 weeks for patients enrolled in both trial periods. There were six phase 3a trials conducted in T2D; two of which also had extension periods. Duration of these trials was 26 or 52 weeks. BEGIN once-long This was a 52-week randomised, controlled, openlabel, multinational, treat-to-target trial, comparing IDeg with IGlar, used in combination with oral antidiabetics (OADs). The study enrolled insulin-naïve adults diagnosed with T2D for 6 months, previously treated with metformin ± a sulphonylurea (SU), glinide, DPP-4 inhibitor (DPP4-I), or α-glucosidase inhibitors (AGI), with dosing unchanged for >3 months. Patients were randomised 3:1 to receive IDeg OD in the evening or IGlar OD at the same time each
5 supplement to Journal of the association of physicians of india january 2014 VOL day, in combination with metformin ± DPP4-I (other OADs were discontinued) 6. The extension period was for 52 weeks more, making the total duration of the trial 104 weeks for patients enrolled in both trial periods. 7 BEGIN early 8 This was a 26-week randomised, controlled, open label, multinational, treat-to-target trial, comparing IDeg with the DPP4-I, sitagliptin as add-on to current OADs. Insulin-naïve patients with T2D for > 6 months and inadequately controlled with 1 2 OADs were eligible. Patients were randomised 1:1 to receive IDeg injected OD (participants could choose the timing as long as they maintained an interval between 8 and 40 hours between injections), or sitagliptin taken OD. All patients continued taking their current OADs. BEGIN BB T2 9 This was a 52-week, randomised, open-label, multinational, treat-to-target trial, comparing IDeg with IGlar, both administered OD in a basal-bolus regimen with IAsp as mealtime insulin ± treatment with metformin, ± pioglitazone. T2D patients with HbA1c % after > 3 months of any insulin regimen (with or without OADs) were included and randomised 3:1 to receive IDeg OD at the main evening meal or IGlar OD at the same time each day, stratified by previous insulin regimen. IAsp was given at breakfast, lunch and dinner and could be given at a fourth meal. BEGIN once asia 10 This was a 26-week, randomised, controlled, openlabel, multinational, treat-to-target trial comparing IDeg OD and IGlar OD, both administered with metformin, SUs, AGIs or glinides. The study enrolled insulin-naïve patients in Asia with T2D for > 6 months who were randomised 2:1 to IDeg OD in the evening or IGlar OD, both as add-on therapy to stable treatment with >1 OAD(s). BEGIN flex 11 This was a 26-week randomised, controlled, openlabel, multinational, three-arm, treat to target trial comparing fixed-flexible dosing of IDeg with IDeg OD and IGlar OD, with or without OADs. The study enrolled patients with type 2 diabetes for > 6 months, and with HbA1c % if previously treated with OADs, or HbA1c % if previously treated with any basal insulin ± OADs. Patients were randomised 1:1:1 to receive either IDeg OD or IGlar OD at the same time each day, or IDeg in a fixed-flexible regimen (IDeg OD Flex), with fixed 8- and 40-hour intervals between injections. BEGIN low volume 12 This was a 26-week, randomised, controlled, openlabel, multinational, treat-to-target trial comparing IDeg in a more concentrated formulation (200 U/mL) with IGlar, both administered OD with metformin with or without a DPP4-I. Insulin-naïve patients diagnosed with T2D for > 6 months were enrolled and randomised 1:1 to receive either IDeg 200 U/mL OD with the main evening meal or IGlar OD at the same time each day. Both insulins were given in prefilled pen devices and in combination with metformin ± DPP4-I treatment as prior to randomisation. Further details on the phase 3a trials are presented in the next article in this supplement, by Mithal et al titled Preserving glycaemic control Insights from BEGIN trials. FlexTouch - New Insulin Delivery Device for Insulin Degludec IDeg is available in FlexTouch (Novo Nordisk A/S, Bagsværd, Denmark), a new prefilled disposable insulin pen and the device used across all trials for the delivery of IDeg. It has a new injection mechanism with no push-button extension. Additional features include an end-of-dose click, a large dose display, dial-back mechanism, a maximum deliverable dose of 80 international units (IU), an ergonomic design, and compatibility with most screw-thread needles. 16 The unique injection mechanism means that a lower injection force is required when injecting with FlexTouch compared with other prefilled insulin pens, at all injection speeds tested. 17,18 FlexTouch also showed consistency and accuracy of dose delivery at minimum, medium and maximum doses (i.e., 1, 40 and 80 U) 19 which should help to minimise glycaemic variations by reducing under- or over-dosing. 18,19 More than 95% of health care providers (HCPs) and patients with diabetes rated FlexTouch as easy to use and hold stable, and responded that it was easy to depress the push-button/plunger and to read the dose scale. 20 In two preference studies among patients with diabetes and HCPs, over 80% of respondents preferred FlexTouch and found it easier to use than comparator pens. 21,22 Dosing and Titration Guidelines Timing 23 IDeg should be injected subcutaneously at any time of the day, preferably at the same time every day. When administration at the same time of the day is not possible, IDeg can be dosed flexibly with a minimum of 8 hours between injections. Initial dosing and adjustments 23 For insulin naïve patients with T2D, recommended
6 26 supplement to Journal of the association of physicians of india january 2014 VOL. 62 initial dose is 10 U which should be adjusted individually thereafter. In T1D, if switching from a previous basal insulin used OD, the initial dose of IDeg can be transferred in a 1:1 ratio for most patients, followed by individual dose adjustment. If the previous basal insulin was used twice daily, or HbA1c < 8.0% at the time of switching, the dose must be determined individually for each patient. In T2D, whether using basal, basal-bolus, premix, or self-mix regimens, IDeg can be transferred in a 1:1 ratio based upon the previous insulin dose, followed by individual dose adjustment. Adjustments made weekly, using the mean of the preceding 3 days SMPG, take into account the fact that it takes IDeg 2 3 days to reach steady state. 24 References 1. Birkeland K, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultralong-acting insulin compared with insulin glargine. Diabetes Care 2011;34: Zinman B, Fulcher G, Rao PT, et al. Insulin degludec, an ultra-longacting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377: Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379: Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycemic control with lower nocturnal hypoglycemia risk than insulin glargine: a 2-year randomized trial in type 1 diabetes. Diabet Med doi: /dme [Epub ahead of print]. 5. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen versus insulin glargine in patients with type 1 diabetes (BEGIN : Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98: Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35: Rodbard H, Zinman B, Cariou B, et al. Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes. Diabetologia 2012;55(Suppl.1):S378(Abstract920). 8. Philis-Tsimikas A, Del Prato S, Satman I et al. Effect of ultra-long-acting insulin degludec versus sitagliptin addition in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obesity Metab 2013;15: Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-totarget non-inferiority trial. Lancet 2012;379: Onishi Y, Iwamoto Y, Yoo SJ. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan Asian, treat-to-target trial. J Diabetes Invest 2013;doi: /jdi [Epub ahead of print]. 11. Meneghini L, Atkin S, Gough S, et al. on behalf of the NN (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed atthe same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013;364: Gough S, Bhargava A, Jain R. Low volume insulin degludec 200 U/ ml once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36: World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009;107: ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 2001;47: US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. (Draft guidance), GuidanceComplianceRegulatoryInformation/Guidances/ ucm pdf. Accessed 15 October Bailey T, Campos C. FlexTouch for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices 2012;9: Hemmingsen H, Niemeyer M, Hansen MR, et al. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther 2011;13: Wielandt JO, Niemeyer M, Hansen MR, et al. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen. Expert Opin Drug Deliv 2011;8: Wielandt JO, Niemeyer M, Hansen MR, et al. FlexTouch : a prefilled insulin pen with a novel injection mechanism with consistent high accuracy at low- (1 U), medium- (40 U), and high- (80 U) dose settings. J Diabetes Sci Technol 2011;5: Campos C, Lajara R, Deluzio T. Usability and preference assessment of a new prefilled insulin pen versus vial and syringe in people with diabetes, physicians and nurses. Expert Opin Pharmacother 2012;13: Oyer D, Narendran P, Qvist M, et al. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv 2011;8: Bailey T, Thurman J, Niemeyer M, et al. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin 2011;27: Tresiba. Summary of product characteristics. Available at: medicines/002498/human_med_ jsp&mid=wc0b01ac d124Accessed October Heise T, Nosek L, Coester H-V, et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012;61(Suppl. 1):A259 Abstract 1013.
Re-Submission: Published 10 March February 2014
Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February
More informationA New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes
A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes Reviewed by Dawn Battise, PharmD STUDIES Initiating insulin degludec (study A): Zinman B, Philis-Tsimikas A, Cariou B, Handelsman
More informationNew Drug Evaluation: Insulin degludec, subcutaneous injection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationChristopher Sorli Mark Warren David Oyer Henriette Mersebach Thue Johansen Stephen C. L. Gough
Drugs Aging (2013) 30:1009 1018 DOI 10.1007/s40266-013-0128-2 ORIGINAL RESEARCH ARTICLE Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with
More informationAuthor proof done. Insulin degludec. Vishakha V. Jain, Omprakash Gupta
Review Article Author proof done Insulin degludec Vishakha V. Jain, Omprakash Gupta Abstract Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationMany people with type 2 diabetes
Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationMedium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Drugs R D (214) 14:133 138 DOI 1.17/s4268-14-48-6 ORIGINAL RESEARCH ARTICLE Medium-Term Effects of Insulin ludec on Patients with Type 1 Diabetes Mellitus Rie Nakae Yoshiki Kusunoki Tomoyuki Katsuno Masaru
More informationOpinion 2 April TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 2 April 2014 TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: 34 009 268
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationS. W. Park 1, W. M. W. Bebakar 2, P. G. Hernandez 3, S. Macura 4, M. L. Hersløv 5 and R. de la Rosa 6. Abstract. Introduction
DIABETICMedicine Research: Treatment Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST â : SIMPLE USE) S. W. Park 1, W. M. W.
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationNew Medicine Assessment
New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationiglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationSwitching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes
Diabetes Management Switching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes Myrey Siuffi D* ABSTRACT Introduction: Degludec (Ideg) is an ultra-long
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHypoglycaemia can cause recurrent morbidity for patients with diabetes. The
supplement to Journal of the association of physicians of india january 2014 VOL. 62 35 Understanding the Safety of the New Ultra Long Acting Basal Insulin A Ramachandran 1, Vishal Gupta 2, Jothydev Kesavadev
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCLINICAL TRIAL. Keywords Basal bolus treatment, Hypoglycemia, Insulin degludec
CLINICAL TRIAL Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice Kazuhiro Kobuke 1,
More informationInsulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )
Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Toujeo uses the same
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationKeywords: b.i.d. treatment, biphasic insulin aspart 30, hypoglycemia, insulin degludec/insulin aspart, type 2 diabetes.
Journal of Diabetes 8 (2016), 720 728 ORIGINAL ARTICLE Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationReview Report. July 10, 2015 Pharmaceuticals and Medical Devices Agency
Review Report July 10, 2015 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product
More informationOTE HAR M A. Insulin degludec (Tresiba ): Ultralong. basal insulin with less nocturnal hypoglycemia than glargine.
HAR M A Vol. 31, Issue 5 February 2016 N OTE Established 1985 Insulin degludec (Tresiba ): Ultra-long basal insulin with less nocturnal hypoglycemia than glargine Brian Nocito, PharmD Candidate D iabetes
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationEffect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
Okada et al. Journal of Pharmaceutical Health Care and Sciences (215) 1:26 DOI 1.1186/s7-15-27-2 RESEARCH ARTICLE Open Access Effect of switching basal insulin regimen to degludec on quality of life in
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationCLINICAL TRIAL. Yukiko Onishi 1,YasuhikoIwamoto 2, Soon Jib Yoo 3, Per Clauson 4 *, Søren C Tamer 5, Sungwoo Park 6
Insulin degludec compared with insulin glargine in insulin-na ıve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial Yukiko Onishi 1,YasuhikoIwamoto 2, Soon
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationIDegAsp provides simple intensification without the addition of another insulin injection and simple delivery system
CASE REPORT Diabetes Management IDegAsp provides simple intensification without the addition of another insulin injection and simple delivery system Shizuka Kaneko*, Youhei Ueda, Yumiko Tahara ABSTRACT
More informationTo assess the safety and tolerability in each treatment group.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationInsulin degludec The impact of a new basal insulin on care in type 2 diabetes
primary care diabetes 8 (2014) 119 125 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Original research Insulin degludec The impact
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationAppropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
https://doi.org/10.1007/s12325-019-00907-8 REVIEW Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist Dhiren Patel. Curtis Triplitt. Jennifer Trujillo Received:
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationImpact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Diabetes Ther (2018) 9:2209 2218 https://doi.org/10.1007/s13300-018-0511-4 ORIGINAL RESEARCH Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety Paola Ponzani. Cesare
More informationManufacturer Proposed indication. Treatment of type 1 diabetes mellitus (T1DM) in adults who require mealtime insulin to control blood glucose levels
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Prescribing Clinical Network Name, brand
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ryzodeg 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationSynopsis. Abstracts submitted to the EASD 2006 and IDF 2006 conferences. 7 June May Phase 4
Report Body and Synopsis Page: 3 of 81 Synopsis TITLE OF TRIAL A 24-week, multi-centre, controlled, open-labelled, parallel, randomised efficacy and safety comparison of biphasic insulin aspart 30 once
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationSponsor: Sanofi. According to template: QSD VERSION N 5.0 (04-APR-2016) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationA randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes
2017, 64 (2), 133-140 Original A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes Tatsuhiko Urakami, Yusuke
More informationDiabetes Care 34: , compromise has to be made in each individual
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
Diabetes, Obesity and Metabolism 14: 859 864, 2012. 2012 Blackwell Publishing Ltd Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type
More informationABSTRACT ORIGINAL RESEARCH. Greg Fulcher. Roopa Mehta. Edmond G. Fita. Magnus Ekelund. Stephen C. Bain
Diabetes Ther (2019) 10:107 118 https://doi.org/10.1007/s13300-018-0531-0 ORIGINAL RESEARCH Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post
More informationABSTRACT. uncontrolled on basal insulin? OADs;
Diabetes Ther (2017) 8:673 682 DOI 10.1007/s13300-017-0252-9 BRIEF REPORT Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationComparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study
Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study Mizuho Yamabe 1, Mami Kuroda 1, Yasuyo Hirosawa 1,HiromiKamino 1, Haruya Ohno
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationoriginal article Introduction
original article Diabetes, Obesity and Metabolism 17: 1142 1149, 215. 215 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Glycaemic control and hypoglycaemia
More informationCONTENT OVERVIEW. 1. Introduction 2. Objectives 3. Methods 4. Results 5. Conclusions
September 2017 COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE U100 IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES FROM THE PERSPECTIVE OF THE SPANISH NATIONAL HEALTHCARE SYSTEM:
More informationOriginal Paper. Pharmacology 2008;82: DOI: /
Original Paper Pharmacology 2008;82:156 163 DOI: 10.1159/000149569 Received: April 14, 2008 Accepted: May 2, 2008 Published online: August 1, 2008 Indirect Comparison of Once Daily Insulin Detemir and
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationCase study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease
Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationStarting Insulin in General Practice
Starting Insulin in General Practice Timothy Kenealy GP & Assoc Prof of Integrated Care, University of Auckland Auckland DHB / my version + Counties DHB version Starting Insulin surprisingly simple, safe
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationA New Option for Glycemic Control: Insulin Degludec, a New-Generation Basal Insulin with an Ultralong Duration of Action
A New Option for Glycemic Control: Insulin Degludec, a New-Generation Basal Insulin with an Ultralong Duration of Action Scott R. Drab 1,2, * and Athena Philis-Tsimikas 3 1 University of Pittsburgh School
More informationA Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
Clin Pharmacokinet (7) :9 DOI.7/s---7 REVIEW ARTICLE A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use Hanne Haahr Edmond
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More information